"Wet Macular Degeneration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.
Concept/Terms
Wet Macular Degeneration- Wet Macular Degeneration
- Degeneration, Wet Macular
- Degenerations, Wet Macular
- Macular Degeneration, Wet
- Macular Degenerations, Wet
- Wet Macular Degenerations
Below are MeSH descriptors whose meaning is more general than "Wet Macular Degeneration".
Below are MeSH descriptors whose meaning is more specific than "Wet Macular Degeneration".
This graph shows the total number of publications written about "Wet Macular Degeneration" by people in Harvard Catalyst Profiles by year, and whether "Wet Macular Degeneration" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 4 | 6 |
| 2012 | 5 | 0 | 5 |
| 2013 | 7 | 0 | 7 |
| 2014 | 10 | 2 | 12 |
| 2015 | 9 | 2 | 11 |
| 2016 | 5 | 1 | 6 |
| 2017 | 8 | 0 | 8 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 0 | 5 |
| 2020 | 10 | 1 | 11 |
| 2021 | 6 | 0 | 6 |
| 2022 | 7 | 0 | 7 |
| 2023 | 3 | 0 | 3 |
Below are the most recent publications written about "Wet Macular Degeneration" by people in Profiles.
-
Extrascleral Extension of Uveal Melanoma Along Intravitreal Needle Tracts Associated With Periodic Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2023 08 01; 141(8):801-803.
-
Ten-Year Incidence of Fibrosis and Risk Factors for Its Development in Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2023 Aug; 252:170-181.
-
Controversies and Disparities in the Management of Age-Related Macular Degeneration. Semin Ophthalmol. 2023 Feb; 38(2):134-142.
-
Severity of age-related macular degeneration at first presentation in Bhutan: a 3-year national study. BMC Ophthalmol. 2022 Jul 09; 22(1):298.
-
The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD. Invest Ophthalmol Vis Sci. 2022 06 01; 63(6):17.
-
Cost Analysis: Port Delivery System versus Monthly Ranibizumab for Wet Age-Related Macular Degeneration Treatment. Ophthalmol Retina. 2022 11; 6(11):1105-1106.
-
Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.
-
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
-
Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2022 May 01; 33(3):131-136.
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.